[Retracted] A Showcase of Bench-to-Bedside Regenerative Medicine at the 2010 ASNTR

Table 2

Summary of Parkinson’s disease studies at the 2010 ASNTR meeting.

	Disease pathology	Models	Neuroprotection	Transplant	Treatments
Morphological Etc	BBB; impairment [5, 6]; Rapid loss of; striatal DA; innervations; [25]; calcium [35]	Rotenone [3, 4]	Uncoupling proteins; [13]	Cografts [33], tissue + calcium channel inhibitors [34], NPCs [36, 37], hMSCs [40]	DA receptor; agonist [24], antidepressants [26],; DBS [27–29]
Gene therapy			𝛼-Synuclein; silencing [14],; pleiotrophin [15]	GDNF + NPCs [38],; GDNF + hUCB [39]
Inflammation	Increased [8, 9, 11]; DA toxicity [12]		Reduced microglial; activation [10]		Allantoin [21] PPAR-; 𝛾 [22]
Growth factors	Fetal-antigen 1; overexpression in; striatum [16]; GDNF and; development [19]		CDNF [20]	GDNF + tissue; grafts [17, 18]